sensitive to changes in response over a shorter period of time than hitherto thought possible. These changes appear to be related to drug concentration. A controlled trial of this concept would be of undoubted value in understanding the psychopharmacology of chlorpromazine.
Effects ofChlorpromazine on Sleep
In a somewhat different study of rapidly reversible chlorpromazine effects, low-dose treatment of four patients with sleep disturbances was carried out (unpublished data). Previously, it had been shown that doses of 100 mg of chlorpromazine improved sleep patterns, while doses of 25 mg had a reverse effect (Lewis & Evans 1969) . In the present study, there was a significant increase in total sleep, and a decrease in intermittent wakefulness, and in early morning wakening, after 100 mg of chlorpromazine at bedtime. In contrast, placebo, and 100 mg of chlorpromazine in the morning, had no effect of this type on sleep patterns. Sleep was in fact slightly worse after chlorpromazineinthemorning than after placebo. Chlorpromazine determinations showed that, at bedtime, chlorpromazine given in the evening resulted in approximately a four-fold higher concentration of drug in plasma than the concentration at bedtime after a dose given in the morning. Thus a genuinely reversible effect of the drug was demonstrated.
It is of interest that, in the above study, the concentration of drug at bedtime after 100 mg of the drug given in the morning compares well with the predicted concentration at bedtime after 25 mg of the drug given in the evening. In the analogous study this dose had a deleterious effect on sleep.
Conclusion
The studies discussed in this report have highlighted a number of important questions in relation to chlorpromazine metabolism and effect, which remain to be answered. Some potentially fruitful fields for further investigation are: (1) The destiny of the drug. This meeting marks a notable turning point in psychiatry and in the use of psychotropic drugs. Psychiatrists have hitherto usually been content to prescribe chlorpromazine, imipramine, or one of the many newer related substances without worrying how the drugs workedif one failed, another could be tried. Dr Curry's careful study shows, however, that measuring the drug plasma level achieved in the individual by a particular treatment can lead to precise modification of dosage to suit that individual and, very important, that chlorpromazine is in some people largely destroyed by gut metabolism before ever it enters the bloodstream. Dr Walter's work on imipramine tends the same way, and is a landmark in the analysis of antidepressant action. It is clear we ought now to be asking our hospital laboratories to set up these estimations routinely so that we can improve our therapy. As some laboratories are already getting gas chromatographs for their poisons identification work they should be in a position to consider using Dr Curry's method. Dr Curry drew attention to the finding that chlorpromazine is rapidly metabolized, which contrasts with its slowness of clinical action. The same is true of imipramine, as we and others have noted. In patients given oral tracer doses ofradioactive imipramine during treatment the plasma even as early as one hour afterwards may contain as much desmethylimipramine and as much iminodibenzyl as it does imipramine (apart from other metabolites), and all three substances can enter the brain. I therefore feel it was bold of Dr Walter to be satisfied with estimating plasma imipramine alone, though his findings are very interesting. I would have liked him to tell us the range of experimental variation in his analyses. Clinically he found that both responders and non-responders had broadly similar complaints of side-effects which we also found (Watt et al. 1969) , which suggests that the antidepressant action of imipramine has a different mechanism from its other actions. Side-effects have not been greatly studied before, and present many problems of assessment. Some side-effects are like symptoms of the disease. And is it reasonable to add them all up to a grand total score for each patient, and even to subtract the score obtained one week before treatment from that obtained another week while on the drug? The necessary work of validation has not been done yet by anyone.
Future progress in the use of psychotropic drugs will depend on paying precise and even quantitative attention to all the human effects of the drug in relation to plasma levels, and sideeffects will have to receive as much consideration as therapeutic effects in this work.
Dr A Todrick (Department ofClinical Research, Crichton Royal Hospital, Dumfries)
The papers presented support the inherent probability of correlation between plasma drug concentration and clinical effect. However, the binding of drugs by plasma proteins must be considered, since the effective concentration at the site of action depends on the level of free rather than total drug in the plasma. Drugs absorbed by plasma proteins are pharmacologically inactive, though in equilibrium with the active fraction. In practice, binding reduces the free concentration but also prolongs the action; it may either extend the time for which an adequate concentration acts or alternatively prevent one ever being attained. The degree of binding can range from almost zero to greater than 99-9 %, the phenothiazines and tranquillizers (75-95 % bound) occupying an intermediate position (Curry 1970 , Campbell & Todrick 1970 . Degree of binding is not the prime correlate of clinical effectiveness but modifies it. While the effective plasma concentrations of these psychotropic drugs are reduced to much the same degree, one should not ignore the possible variation with both drug and subject.
We sympathize with Dr Walter's difficulty in obtaining patients fitting his highly desirable clinical criteria, having ourselves met this problem in an acute form. The significant correlations obtained, despite small numbers, suggest that the underlying connexion must be close. On the basis of these and Dr Curry's observations, plasma concentration can now be accepted as superior to dose as a reflection of clinical effectiveness. It may be too early to demand plasma drug estimations routinely but research must undoubtedly continue.
In the relationship of plasma drug concentration to therapeutic action, the time factor has often appeared confusing. Dr Walter has observed a biphasic relationship between plasma concentration and duration of therapy; this may arise from induction of hydroxylating enzyme; if so, it should be absent in patients already on barbiturates. Like Dr Curry, I am puzzled by the delay in response to a stabilized chlorpromazine level. The theory that inactive precursors are converted to active metabolites is no longer favoured. We used to believe that much time was required to achieve a high brain level from a low free plasma concentration but the evidence is against it. It may be necessary to assume that the development of schizophrenia and depressive illness is only partially physiological or biochemical and that a second stage involves learning ofor conditioning forincorrect behaviour patterns. Pharmacological removal of the conditioning stimulus would leave the patient still incorrectly patterned, and unlearning would take time.
